Research Article

Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients

Table 2

Progression-free survival rate age at 3 and at 6 months, the mean and median number of treatment cycles received, the parametric description of survival with the lognormal distribution, and average survival times. The estimated average survival time with the lognormal distribution is calculated by exp (μ + σ2/2).

Progression-free survivalL-SarcomaNon-L-sarcoma
TrabectedinIfosfamideTrabectedinIfosfamide

PFS probability (%)At 3 months59.547.437.551.6
At 6 months41.715.818.822.6
N treatment cyclesMean6.13.83.83.4
Median6433

Parametric analysis of survival
PFSμ1.501.081.001.20
σ1.051.051.041.04
Average PFSIn months7.755.074.645.71
In years0.650.420.390.48
OSμ2.422.151.772.21
σ1.001.000.940.94
Average OSIn months18.5814.179.0914.18
In years1.551.180.761.18

PFS: progression-free survival; OS: overall survival.